Sort
10,766 grants matching “checkpoint inhibitor”
Antitumor-Antibiotics from Marine Microorganisms
$99,839William Fenical · University Of California, San Diego · R37 · FY2009 · CA
The replication checkpoint and genomic fidelity in skin
$99,792Paul Nghiem · University Of Washington · K02 · FY2006 · AR
The replication checkpoint and genomic fidelity in skin
$99,792Paul Nghiem · University Of Washington · K02 · FY2008 · AR
The replication checkpoint and genomic fidelity in skin
$99,792Paul Nghiem · University Of Washington · K02 · FY2007 · AR
Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface
$99,353Melody A Swartz · University Of Chicago · R01 · FY2025 · CA
Exploring the potential of TET inhibition in cancer immunotherapy
$99,352Anjana Rao · La Jolla Institute For Immunology · R01 · FY2024 · CA
Durvalumab in Combination with Olaparib in Non-Small Cell Lung Cancer
$99,323Arun Rajan · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection
$99,295Harris Goldstein · Albert Einstein College Of Medicine · R01 · FY2023 · AI
Amplifying and Redirecting CMV-specific CD8 T cells to provide sustained control of HIV infection
$99,295Harris Goldstein · Albert Einstein College Of Medicine · R01 · FY2024 · AI
Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma
$99,216Amanda Johnson · Dana-Farber Cancer Inst · K00 · FY2025 · CA
Defining tumor and blood-based immunogenomic signatures predicting response to immunotherapy in ovarian cancer
$99,171Kelsey R Monson · Icahn School Of Medicine At Mount Sinai · K00 · FY2025 · CA
Profiling and leveraging bystander T cells within the tumor microenvironment
$99,010Nicholas Joseph Maurice · University Of Minnesota · K00 · FY2025 · CA
Core A: Administration, Integration, Education and Career Development
$98,756Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2023 · CA
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
$98,752Meghan E. Sise · Massachusetts General Hospital · R01 · FY2024 · DK
(PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockade
$98,415Adam Mor · Columbia University Health Sciences · R21 · FY2020 · CA
Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck Cancer
$98,338Barbara Burtness · Yale University · P50 · FY2023 · DE
Biological and Therapeutic Consequences of RNA Dysregulation in Cancer Immune Evasion
$98,113James Douglas Thomas · University Of Florida · K99 · FY2022 · CA
Cancer Immunology and Immunotherapy Program
$98,091Keith L Knutson · Mayo Clinic Rochester · P30 · FY2022 · CA
Cancer Immunology and Immunotherapy Program
$97,967Keith L Knutson · Mayo Clinic Rochester · P30 · FY2023 · CA
Cancer Immunology and Immunotherapy Program
$97,967Keith L Knutson · Mayo Clinic Rochester · P30 · FY2021 · CA
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$97,849Alfred Ayala · Rhode Island Hospital · R35 · FY2024 · GM
Leveraging gnotobiotic models to study the gut microbiota and anti-tumor immunity
$97,722Jessica Lynn Fessler · Stanford University · K00 · FY2023 · CA
Controlled Antigen Delivery for Prophylactic Cancer Vaccination
$97,672Brett Pogostin · Massachusetts Institute Of Technology · K00 · FY2025 · CA
RNA editing in islet function and inflammation
$97,632Alvin Carter Powers · Vanderbilt University Medical Center · R01 · FY2025 · DK
Reversal of T cell Exhaustion
$97,500Linda Mac Pherson Bradley · Sanford Burnham Prebys Medical Discovery Institute · R03 · FY2017 · AI